Greetings To All, New Member Here - Let's chat.
Hello everyone, first time post. On Friday I entered into SVFC with a modest 320,000 share purchase. I understand that there is currently some legal wrangling between SVFC and IR. That's not really what I want to talk about, as many of you have made very valid points and poignant observations, of which I have little to add. I am no stranger to legal binary events (I rode VHC up to the apple verdict...a white-knuckle ride that paid off), nor am I a stranger to developmental (clinical) stage biotech companies (I also currently maintain a hefty position in SGYP). What I want some clarification on is future revenue stream.
Specifically, how can/will the technologies being developed by SVFC be marketed? Will it be as a service (I.e., one goes to SVFC, and, in coordination with their PCP, undergoes the process of donation of cells, culturing of desired cells, and then finally treatment via the rendered cells [presumably in a hospital setting])? Or will it rather be in the sale of the procedure itself (I.e. SVFC, via their patented process, allows medicinal facilities worldwide to use their procedure in accordance with a licensing agreement more in line with traditional USPTO [and equivalent international bodies] IP licensing)?
I'm not presenting such options as mutually-exclusive, of course, but I would like some clarification on SVFC's modus operendai going forward. Any thoughts or observations would be appreciated. I was hesitant on getting involved in this forum, as more often than not such discussions devolve into longs and shorts pumping or attacking a stock in the face of evidence, with no better understanding gained. I hope that won't be the case this time.
Other lingering questions I have that would serve as constructive discussion fodder: in pursuing FDA approval, will each treatment option utilizing SVFC's process need be studied independently? (I.e., a clinical study focusing on JUST treatment of heart attacks, a clinical study focusing on JUST treatment of MS, etc.) Or perhaps the process itself may gain approval independent on which treatments specifically work and which don't (I.e., the process itself becomes approved, THEN the efficacy of each treatment is examined)?
Thanks in advance for your input, and nice to meet you.
Sincerely,
Ionthefuture
